RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCapital Medical University
About this trial
This is a Phase II/III randomized clinical trial of Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology (RAPART) in locally advanced non-small cell lung cancer patients. The main objective is to test the overall improvement of overall survival (OS), progression free survival (PFS), and local progression free survival (LPFS) of unresectable stage III NSCLC under standard and non-standard mixed treatment conditions compared to conventional 60Gy radiotherapy.
Eligibility criteria
Qualifiers
Adult research participants, aged over 18 years old;
Non small cell lung cancer that requires pathological confirmation;
All stage 3 unresectable non-small cell lung cancer, including stage correction after MDT and stage downgrading after treatment (4 → 3), and stage upregulation due to disease progression (2 → 3);
ECOG physical condition is 0-2;
Disqualifiers
Prisoners who are not convenient for close clinical follow-up;
Study participants with contraindications to radiation therapy.
Trial design
Treatments tested in this trial
- Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology（RAPART)）
- Conventional radiotherapy
Treatment groups
911 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov